Physicians' Academy for Cardiovascular Education

How do GLP-1RAs work?

5 Things a cardiologist needs to know about GLP-1RA

New - subtitling in English, German, Italian, Spanish, French, and Chinese

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD – Glasgow, UK

Video navigation menu

  • GLP-1 production and glucose-stimulated insulin release 00:34
  • Mechanism of action of GLP-1RA and effect of chemical modifications 01:21
  • Effect of GLP-1RA on appetite and gastric emptying 02:29
  • Are CV benefits of GLP-1RA fully explained by observable changes in risk factors? 03:30
  • GLP-1RA CV Outcomes Trials 05:50

Transcript

Show transcript

Educational information

This educational video is part of a series called '5 Things a cardiologist needs to know about GLP-1RA' that are aimed to guide cardiologists in management of patients with type 2 diabetes, since the cardiology practice is increasingly confronted with these patients. This series covers five topics that help cardiologists understand why GLP-1 RAs are promising as multifactorial treatment for patients with T2D and/or obesity and CVD, and to improve clinical implementation of guidelines recommending treatment with anti-diabetic drugs with CV benefit.

Faculty

Naveed Sattar, MD is Professor of Metabolic Medicine, University of Glasgow. He is an academic (active clinically) experienced in biomarker studies/trials investigating the causes, prevention and management of diabetes, obesity and heart disease.

Disclosures

This recording was developed under auspices of PACE-cme. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk A/S.

Podcast of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: